

Matthias Kroiss

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6045937/publications.pdf>

Version: 2024-02-01

92
papers

6,682
citations

81900

39
h-index

64796

79
g-index

95
all docs

95
docs citations

95
times ranked

5950
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination Chemotherapy in Advanced Adrenocortical Carcinoma. <i>New England Journal of Medicine</i> , 2012, 366, 2189-2197.	27.0	692
2	Integrated genomic characterization of adrenocortical carcinoma. <i>Nature Genetics</i> , 2014, 46, 607-612.	21.4	560
3	Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers. <i>New England Journal of Medicine</i> , 2020, 383, 825-835.	27.0	454
4	Update in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4551-4564.	3.6	346
5	Adrenocortical carcinoma: a clinician's update. <i>Nature Reviews Endocrinology</i> , 2011, 7, 323-335.	9.6	336
6	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 841-849.	3.6	274
7	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. <i>Lancet Oncology</i> , 2015, 16, 426-435.	10.7	272
8	Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. <i>Annals of Oncology</i> , 2015, 26, 2119-2125.	1.2	196
9	A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. <i>New England Journal of Medicine</i> , 2018, 379, 428-439.	27.0	180
10	Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. <i>Endocrinology</i> , 2015, 156, 3895-3908.	2.8	153
11	Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3495-3503.	3.6	146
12	The Role of Surgery in the Management of Recurrent Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 181-191.	3.6	132
13	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021, 11, 2780-2795.	9.4	125
14	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. <i>European Urology</i> , 2014, 65, 832-838.	1.9	121
15	Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2010, 162, 349-356.	3.7	119
16	Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. <i>European Journal of Endocrinology</i> , 2013, 169, 263-270.	3.7	118
17	Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. <i>Clinical Endocrinology</i> , 2011, 75, 585-591.	2.4	110
18	Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1686-1695.	3.6	105

#	ARTICLE	IF	CITATIONS
19	Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic pheochromocytoma. <i>Annals of Clinical Biochemistry</i> , 2013, 50, 147-155.	1.6	99
20	Evolution of an RNP assembly system: A minimal SMN complex facilitates formation of UsnRNPs in <i>Drosophila melanogaster</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10045-10050.	7.1	92
21	Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4511-4523.	3.6	92
22	Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. <i>European Journal of Endocrinology</i> , 2016, 175, 521-529.	3.7	90
23	Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22269-22274.	7.1	81
24	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4323-4332.	3.6	79
25	Tdrd3 is a novel stress granule-associated protein interacting with the Fragile-X syndrome protein FMRP. <i>Human Molecular Genetics</i> , 2008, 17, 3236-3246.	2.9	77
26	The landscape of chromothripsis across adult cancer types. <i>Nature Communications</i> , 2020, 11, 2320.	12.8	75
27	Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients. <i>Clinical Nuclear Medicine</i> , 2017, 42, e29-e34.	1.3	60
28	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. <i>Genetics in Medicine</i> , 2019, 21, 705-717.	2.4	60
29	Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. , 2020, 8, e000469.		59
30	Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2019, 180, 117-125.	3.7	59
31	No endogenous ouabain is detectable in human plasma by ultra-sensitive UPLC-MS/MS. <i>Clinica Chimica Acta</i> , 2014, 431, 87-92.	1.1	58
32	Prognostic impact of subclinical thyroid dysfunction in heart failure. <i>International Journal of Cardiology</i> , 2013, 168, 300-305.	1.7	57
33	Thyroid Function, Cardiovascular Events, and Mortality in Diabetic Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2014, 63, 988-996.	1.9	57
34	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1440.	7.1	57
35	A Novel Syndrome of Mandibular Hypoplasia, Deafness, and Progeroid Features Associated with Lipodystrophy, Undescended Testes, and Male Hypogonadism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E192-E197.	3.6	56
36	Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. <i>European Journal of Endocrinology</i> , 2015, 172, 251-260.	3.7	47

#	ARTICLE	IF	CITATIONS
37	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 102, jc.2016-3205.	3.6	44
38	Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany. <i>Deutsches Arzteblatt International</i> , 2010, 107, 885-91.	0.9	44
39	Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 109-116.	1.2	43
40	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. <i>PLoS ONE</i> , 2014, 9, e105855.	2.5	41
41	S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. <i>European Journal of Endocrinology</i> , 2022, 186, 25-36.	3.7	41
42	Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1461-1468.	3.6	39
43	Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. <i>Cell Death and Disease</i> , 2020, 11, 192.	6.3	39
44	EJE PRIZE 2014: Current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?. <i>European Journal of Endocrinology</i> , 2014, 171, R1-R11.	3.7	37
45	High-Resolution Tissue Mass Spectrometry Imaging Reveals a Refined Functional Anatomy of the Human Adult Adrenal Gland. <i>Endocrinology</i> , 2018, 159, 1511-1524.	2.8	37
46	The role of regulated necrosis in endocrine diseases. <i>Nature Reviews Endocrinology</i> , 2021, 17, 497-510.	9.6	35
47	Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades. <i>Clinical Endocrinology</i> , 2017, 87, 320-326.	2.4	32
48	Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study. <i>BMC Cancer</i> , 2017, 17, 522.	2.6	29
49	Transporter regulator RS1 (<i>RSC1A1</i>) coats the <i>trans</i> -Golgi network and migrates into the nucleus. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, F1201-F1212.	2.7	28
50	Is There a Role for Laparoscopic Adrenalectomy in Patients with Suspected Adrenocortical Carcinoma? A Critical Appraisal of the Literature. <i>Hormone and Metabolic Research</i> , 2013, 45, 130-136.	1.5	27
51	Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. <i>Endocrine-Related Cancer</i> , 2015, 22, 531-543.	3.1	27
52	Predictive Value of ¹⁸ F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib. <i>Journal of Nuclear Medicine</i> , 2018, 59, 756-761.	5.0	26
53	The adrenal specific toxicant mitotane directly interacts with lipid membranes and alters membrane properties depending on lipid composition. <i>Molecular and Cellular Endocrinology</i> , 2016, 428, 68-81.	3.2	25
54	Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2017, 177, 227-237.	3.7	23

#	ARTICLE	IF	CITATIONS
55	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. <i>Cancers</i> , 2020, 12, 359.	3.7	23
56	Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. <i>Annals of Surgical Oncology</i> , 2019, 26, 531-538.	1.5	22
57	Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2016, 174, 343-353.	3.7	20
58	Functional Implications of LH/hCG Receptors in Pregnancy-Induced Cushing Syndrome. <i>Journal of the Endocrine Society</i> , 2017, 1, 57-71.	0.2	20
59	Survivin in Adrenocortical Tumors - Pathophysiological Implications and Therapeutic Potential. <i>Hormone and Metabolic Research</i> , 2013, 45, 137-146.	1.5	19
60	Prognostic Relevance of Steroid Sulfation in Adrenocortical Carcinoma Revealed by Molecular Phenotyping Using High-Resolution Mass Spectrometry Imaging. <i>Clinical Chemistry</i> , 2019, 65, 1276-1286.	3.2	19
61	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1111-e1128.	3.6	19
62	Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome. <i>Clinical Chemistry</i> , 2021, 67, 998-1007.	3.2	18
63	Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2642-2653.	3.6	18
64	Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. <i>Hormones and Cancer</i> , 2016, 7, 211-218.	4.9	16
65	Enzyme autoinduction by mitotane supported by population pharmacokinetic modeling in a large cohort of adrenocortical carcinoma patients. <i>European Journal of Endocrinology</i> , 2018, 179, 287-297.	3.7	15
66	Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 578-584.	1.2	15
67	A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 3951-3962.	3.7	14
68	A Micellar Mitotane Formulation with High Drug Loading and Solubility: Physicochemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models. <i>Macromolecular Bioscience</i> , 2020, 20, e1900178.	4.1	14
69	Volumetric and texture analysis of pretherapeutic 18F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib. <i>Endocrine</i> , 2019, 63, 293-300.	2.3	13
70	Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. <i>Hormones and Cancer</i> , 2016, 7, 345-355.	4.9	12
71	Native purification of protein and RNA-protein complexes using a novel affinity procedure. <i>Fly</i> , 2009, 3, 223-231.	1.7	10
72	Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2239-e2246.	3.6	10

#	ARTICLE	IF	CITATIONS
73	High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, , .	3.9	10
74	Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using 18F-FDG positron emission tomography. <i>Endocrine</i> , 2016, 53, 791-800.	2.3	8
75	Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane. <i>Molecular and Cellular Endocrinology</i> , 2019, 480, 36-41.	3.2	8
76	Reassessment of Postural Stimulation Testing as a Simple Tool to Identify a Subgroup of Patients With Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e865-e873.	3.6	7
77	Inhibition of Cholesterol Esterification in the Adrenal Gland by ATR101/PD132301â€², A Promising Case of Drug Repurposing. <i>Endocrinology</i> , 2016, 157, 1719-1721.	2.8	5
78	Abiraterone Acetate for Cushing Syndrome: Study in a Canine Primary Adrenocortical Cell Culture Model. <i>Endocrinology</i> , 2018, 159, 3689-3698.	2.8	4
79	PKA CÎ± subunit mutation triggers caspase-dependent RlÎ² subunit degradation via Ser ¹¹⁴ phosphorylation. <i>Science Advances</i> , 2021, 7, .	10.3	4
80	Steroid Sulfation in Adrenal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3385-3397.	3.6	4
81	Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitorsâ€”A Retrospective Multi-Center Registry Analysis. <i>Cancers</i> , 2022, 14, 3405.	3.7	4
82	ATR-101 phase 1 clinical study for adrenocortical carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4585-TPS4585.	1.6	3
83	Localization of deformable tumors from shortâ€”arc projections using Bayesian estimation. <i>Medical Physics</i> , 2012, 39, 7205-7214.	3.0	2
84	Mitotane induces endoplasmic reticulum stress triggering apoptosis and decrease of steroid hormone synthesis. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, .	1.2	1
85	Transient pregnancy-induced Cushing's Syndrome with Aberrant Adrenal hCG receptor. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, .	1.2	1
86	Survival of Patients with Adrenocortical Carcinoma (ACC) after Radical Resection Revisited.. , 2010, , P3-78-P3-78.		0
87	Expression of CYP2W1 in the adrenal gland: relationship with hormone secretion and clinical outcome. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, .	1.2	0
88	Treatment of refractory adrenocortical carcinoma with thalidomide: results of a retrospective analysis of 15 patients. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, .	1.2	0
89	Towards a registry for rare malignant tumors of the thyroid. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, .	1.2	0
90	Prognostic factors of overall survival of stage III or IV adrenocortical carcinomas (ACC): A multicenter ENS@T study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4106-4106.	1.6	0

#	ARTICLE	IF	CITATIONS
91	FGF-21 levels in polyuria-polydipsia syndrome. <i>Endocrine Connections</i> , 2018, 7, 1501-1506.	1.9	0
92	Objective response and prolonged stable disease in refractory adrenocortical carcinoma treated with cabozantinib: An international case series and protocols of phase II clinical trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16118-e16118.	1.6	0